A circulating tumor DNA (ctDNA) test showed promise in identifying which older patients with estrogen receptor–positive ...
Retrospective analysis of ctDNA results from real-world data was performed for 61 patients (233 plasma time points) diagnosed with early-stage UC. ctDNA status and dynamics were assessed using a ...
Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes. We ...
A blood test for circulating tumor human papillomavirus DNA (ctHPVDNA) may improve risk assessment in patients undergoing ...
SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...
People battling throat cancer may gain extra guidance on their treatment with DNA blood tests taken before and after ...
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove ...
Medindia on MSN
Novel ctDNA blood test to track and treat prostate cancer
India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is circulating tumor DNA, often called ctDNA, which is gaining attention in ...
Evexia Diagnostics now offers 20/20 BioLabs’ OneTest™ MCED test, giving clinicians affordable, biomarker insights for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results